BCV
KYTX icon

Banque Cantonale Vaudoise’s Kyverna Therapeutics KYTX Stock Holding History

Banque Cantonale Vaudoise’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$263K Buy
+30,532
New +$254K 0.01% 595

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Banque Cantonale Vaudoise's KYTX Position: Q1 2026 in Review

Banque Cantonale Vaudoise opened a new position in Kyverna Therapeutics (KYTX) in Q1 2026: 30,532 shares worth $263K. The stake represents 0.01% of the portfolio and ranks #595 among its holdings.

111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Banque Cantonale Vaudoise held 30,532 shares of Kyverna Therapeutics worth $263K as of Q1 2026.
  • Kyverna Therapeutics was a new Banque Cantonale Vaudoise position in Q1 2026.
  • Kyverna Therapeutics made up 0.01% of Banque Cantonale Vaudoise's portfolio in Q1 2026, its #595 holding.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Banque Cantonale Vaudoise's 13F filing for Q1 2026, filed 20 Apr 2026.